Back to dashboard
CommercialCoverageLow impact

08.01.96a, olipudase alfa-rpcp (Xenpozyme®)

Independence Blue Cross·Endocrinology, Pediatrics·Pharmacy
Effective date
Apr 1, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

Policy for olipudase alfa-rpcp (Xenpozyme®), a pharmacy medication, has been reissued and will take effect April 1, 2026. This appears to be a routine policy update for this specialized medication used to treat acid sphingomyelinase deficiency.

Action Required

Action needed
By March 31, 2026: Review updated policy 08.01.96a for olipudase alfa-rpcp (Xenpozyme®) at the provided URL to understand any changes to coverage criteria, prior authorization requirements, or billing procedures for this specialized medication. Update any relevant protocols in billing system if changes are identified.

Related policy hubs